- Home
- PSNYW vs ABEO Comparison
PSNYW vs ABEO Comparison
Compare PSNYW & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNYW | ABEO |
|---|---|---|
| Founded | 2017 | 1974 |
| Country | Sweden | United States |
| Employees | 2547 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 312.6M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PSNYW | ABEO |
|---|---|---|
| Price | $3.47 | $5.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 4.2K | ★ 1.0M |
| Earning Date | 03-06-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | ★ $2,034,261,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | $79.49 | $145.42 |
| P/E Ratio | ★ N/A | $5.45 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $0.14 | $4.00 |
| 52 Week High | $7.50 | $7.54 |
Technical Indicators
Market Signals| Indicator | PSNYW | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 58.61 |
| Support Level | $3.39 | $5.24 |
| Resistance Level | $4.60 | $5.62 |
| Average True Range (ATR) | 0.32 | 0.24 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 25.71 | 68.15 |
Price Performance
Historical ComparisonAbout PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.